How Pharma Majors like Pfizer Inc. (PFE), Johnson & Johnson (JNJ) And Merck & Co. Inc. (MRK) Are Responding To Alzheimer?

CNBC’s Meg Tirrell reported on the popular “Squawk Box” program that patients suffering from Alzheimer disease in U.S and across the globe are assuming epidemic proportions with “5 million people currently have Alzheimer’s in the united states” alone and has been estimated to have been the “sixth leading cause of death” in the country. The talk show participants then went on to discuss how pharma majors from across the globe like Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Merck & Co., Inc. (NYSE:MRK) have responded to this medical crisis.

Pfizer Inc. (NYSE:PFE)

The discourse on “Squawk Box” pointed out that currently available drugs “treat the symptoms” of Alzheimer and also pointed out the challenges faced by the multinational drug companies in producing drugs which address the “underlying cause of the disease”.

The program also threw light on the fact that close to 35.6 million patients are suffering from the old age disease of “Alzheimer’s or dementia” worldwide and even more worrisome are the expert estimates that its occurrence in patients is “expected to triple by 2050.”

Tirrell and her program guests then went on to discuss in detail the challenges that Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and their peers are facing in designing drugs which prevent the occurrence of  Alzheimer’s by explaining that, “ we actually don’t know what causes it. We don’t understand the biology well enough beneath this disease to be able to treat it well.”

The program then went on to express hope on a effective drug being discovered by the likes of Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Merck & Co., Inc. (NYSE:MRK) in the near future by pointing out to the strong drug candidate pipelines these drug majors are working on currently. The participants pointed out that, “There’s 67 medicines in development, up from 22 in 2004.”

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!